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SUMMARY 
86% of IgG heavy-chain gene transcripts were found to be non-functional in the 
peripheral blood B-cells of a patient initially diagnosed with common variable 
immunodeficiency, who later developed raised IgM, whereas no non-functionally 
rearranged transcripts were found in the cells of seven healthy control subjects. 
All the patient’s IgM heavy-chain and κ light-chain transcripts were functional, 
suggesting that either non-functional rearrangements were being selectively class-
switched to IgG, or that receptor editing was rendering genes non-functional after 
class-switching. The functional γ-chain sequences showed a normal rate of 
somatic hypermutation while non-functional sequences contained few somatic 
mutations, suggesting that most came from cells that had no functional gene and 
therefore were not receiving signals for hypermutation. However, apoptosis of 
peripheral blood lymphocytes was not impaired. No defects have been found in 
any of the genes currently known to be responsible for hyper-IgM syndrome but 
the phenotype fits best to type 4. 
 2
Abbreviations not listed by Biochemical Journal: 
 
Ab  antibody 
CSR  class-switch recombination (isotype-switching) 
CVI  common variable immunodeficiency 
Cγ  IgG constant region 
Cμ   IgM constant region 
dNTP  deoxyribonucleotide triphosphate 
HCDR3 Ig heavy-chain complementarity-determining region 3 
HBSS  Hanks’ Balanced Salt Solution 
HIGM  Hyper-IgM syndrome 
mAb  monoclonal antibody 
PBL  peripheral blood lymphocytes 
PBMC  peripheral blood mononuclear cells 
PE  phycoerythrin 
RSS  recombination signal sequence(s) 
r.t.  room temperature 
SHM  somatic hypermutation 
V-genes variable region gene elements 
γ-chain IgG heavy-chain 
μ-chain IgM heavy-chain 
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INTRODUCTION 
    Common variable immunodeficiency (CVI) and hyper-IgM syndrome (HIGM) 
both present with recurrent infections. In the former they are mainly bacterial 
whereas, in the latter, opportunistic parasitic and fungal infections are also 
common. CVI is the commonest symptomatic primary Ab-deficiency disorder.1 
By the standard criteria, the peripheral blood has IgG and IgA at least two 
standard deviations below the mean for age and sex (typically < 5 g/L and < 0·1 
g/L respectively) and IgM may be low or within normal limits.2-5 Its diagnosis is 
made by the exclusion of all secondary causes of immunodeficiency, and by lack 
of typical features of known single-gene disorders. Thus it is usually made on 
clinical and immunological grounds, rather than by genetic testing. The cause is 
unknown but it has been realised for a long time that it is heterogeneous.1 
    HIGM is less common. It exhibits low serum IgG, IgA and IgE along with a 
raised or normal IgM concentration and therefore may sometimes be confused 
with CVI. It is also heterogeneous.6 Mutations in five genes have so far been 
identified as causing this syndrome. Of these the commonest cause is mutation of 
the CD154 (CD40 ligand) gene, TNFSF5, responsible for an X-linked form, 
HIGM1 (also previously known as X-HIGM).7-12 CD154 is normally expressed 
transiently on the surface of activated T-cells, and the absence of CSR is due to 
failure of T-cell signalling to B-cells.13 HIGM2 is autosomal recessive and caused 
by mutations in the activation-induced cytidine deaminase gene, AICDA, (AID, 
CDA2).14 It is characterised by absence of CSR, lack of SHM, and lymph-node 
hyperplasia with giant germinal centres. Unlike types 1 and 3, opportunistic 
infections are not a feature of this type. HIGM3 is also autosomal recessive and is 
caused by mutations in the CD40 gene, TNFRSF5.15 All cases reported so far 
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exhibit lack of expression of CD4015,16 and also display lack of CSR, deficient 
SHM, and impaired generation of memory B-cells. 
    Recently, mutations in UNG (the uracil DNA glycosylase gene) have been 
found in three HIGM patients who lacked any of the above mutations.17 These 
patients showed a profound impairment of CSR and a disturbance of the pattern of 
SHM; there was a deficit in transversion mutations of C·G base-pairs, compared 
with transitions, but no transition-transversion bias in mutations of A·T base-
pairs. This condition is also autosomal recessive. Finally, a variety of mutations in 
the NF-κB essential modulator (NEMO) gene, IKBKG (aliases: IP2, FIP3, 
NEMO, FIP-3, Fip3p, IKK-gamma), cause an X-linked primary 
immunodeficiency characterized by hyper-IgM syndrome and hypohydrotic 
ectodermal dysplasia (XHM-ED, alias HEM-ID for hypohydrotic ectodermal 
dysplasia with immunodeficiency).18-21 These patients’ B cells are also unable to 
undergo CSR. 
    These latter two genetic entities may become known as HIGM5 and HIGM6 
because the term HIGM4 has already been associated with yet another form of 
HIGM, for which the gene has not yet been identified.22 This is a somewhat 
milder form symptomatically, clinically resembling HIGM2, including lymphoid 
organ hyperplasia but without giant germinal centres. CSR is impaired but there is 
some residual IgG production, and SHM is normal. 
    HIGM1 and HIGM3 are clinically indistinguishable15 and are combined 
immunodeficiencies.6,16 NEMO is involved in CD40-induced activation of the 
transcription factor NF-κB and hypomorphic mutations in it affect both T- and B-
cells.21 The other three types of HIGM described so far involve only B-cells. 
AICDA is necessary for both CSR and SHM.14,23 Though CSR is absent in 
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HIGM1, a subset of B-cells do exhibit SHM.24 It appears therefore that the CD40-
ligand-CD40 interaction does not turn on AICDA expression but rather that it acts 
on a pathway downstream of AICDA that leads to CSR but not to SHM. UNG 
mutations clearly act downstream of AICDA in both pathways. The mechanism 
proposed is that AICDA deaminates cytosine to uracil in targeted DNA in Ig 
variable regions and switch regions and that UNG removes the uracil.17 The 
defect in HIGM4 must also act downstream of AICDA (which is expressed 
normally) and appears to act in the CSR pathway only, as SHM is unaffected.22 
   Levy and colleagues25,26 found that a subgroup of CVI patients have greatly 
reduced somatic mutation of their rearranged IgG heavy-chain genes, and that the 
mean mutation rate of these genes in the rest of their CVI patients was slightly 
below the mean rate in their healthy controls. From this one can infer that 
immunodeficiency in these patients may be due to poor affinity maturation 
resulting from reduced hypermutation. A study of hypermutation rates in CVI 
patients here revealed a patient whose rearranged IgG heavy-chain transcripts 
were nearly all non-functional, with the few functional ones having a normal 
hypermutation rate. All of the patient’s IgM heavy-chain transcripts were 
functional. Thus, in this case, the immunodeficiency appears to be due to a very 
small IgG repertoire because there are very few functional rearrangements. The 
finding that a high proportion of IgG heavy-chain rearrangements are non-
functional is extremely unusual. In seven healthy controls, no non-functionally 
rearranged γ-chain transcripts were found. Since diagnosis the patient’s serum 
IgM has become raised. As SHM is normal, the pattern may best approximate to 
HIGM4. We present an analysis of the patient’s rearranged genes and other 
investigations. 
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 MATERIALS AND METHODS 
Patient and healthy controls 
As part of a survey of somatic hypermutation rates in CVI, peripheral blood was 
obtained from a patient diagnosed as having CVI and attending hospital for 
regular Ig infusions, and from seven healthy controls (working in our department). 
The patient is a 44-year-old man referred at age 39 with a history of upper and 
lower respiratory tract infections since adolescence, including otitis media and 
sinusitis, recurrent bronchitis and one episode of pneumonia. He also experienced 
recurrent conjunctivitis. In the four years prior to presentation, cervical 
lymphadenopathy had accompanied the upper respiratory tract infections, usually 
resolving completely with antibiotic therapy, but on one occasion precipitating 
lymph-node biopsy, which demonstrated reactive hyperplasia. There was no 
family history of immunodeficiency or recurrent infection. At the time of 
diagnosis he had daily purulent sputum production but no dyspnoea. No 
lymphadenopathy or other abnormality was present on physical examination. 
Haematological and radiological investigations excluded lymphoma. 
Immunoglobulin studies demonstrated IgG 0·08 g/L (normal range 5·0 – 16·0 g/L) 
IgA , 0·07 g/L (normal range 0·80 – 4·0 g/L), IgM 1·87 g/L (normal range 0·5 – 
2·0 g/L) and no serum paraprotein. Routine peripheral blood lymphocyte 
phenotyping at the time revealed a total lymphocyte count of 2·04 × 109/L, total T-
cells (CD3+) 1·41 × 109/L (69%), total B-cells (CD19+) 0·102 × 109/L (5%) and 
total NK (CD16+CD56+) 0·469 × 109/L (23%). B-cells were, and have remained, 
polyclonal with respect to κ/λ expression, and there has been no evidence of the 
presence of a clonal lymphocyte population in the peripheral blood. Lymphocyte 
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proliferative responses to mitogens, phytohaemaglutinin, concanavalin A and 
pokeweed mitogen were normal in comparison to a healthy control. 
    A diagnosis of CVI was made and he was commenced on intravenous 
replacement Ig infusions every three weeks. His subsequent course was 
characterised by decreased frequency of infections with the achievement of 
normal IgG levels. Eighteen months after diagnosis his IgM became raised, and 
since then, while it has varied between 1·94 and 6·02 g/L, the overall trend has 
been upward, though it remains polyclonal. However, testing for known genetic 
forms of hyper-IgM syndrome has been negative (see Results). Cervical 
lymphadenopathy has recurred intermittently and has prompted further biopsy but 
again only demonstrated reactive changes histologically. Unilateral parotid 
swelling has been present intermittently, biopsy has excluded malignant change, 
and the patient is under regular clinical and radiological review. There is a six-
month history of xerophthalmia. The fluctuations in IgM levels have not 
correlated with recurrences of lymphadenopathy or parotid swelling, or any other 
clinical feature. 
 
Cell preparation 
PBMC were prepared from whole blood, anticoagulated with EDTA or heparin by 
centrifugation through Histopaque 1077 (Sigma Diagnostics). 
 
Cytometry 
For measurement of IgG+ B-cells, 0·5 ml of whole blood, anticoagulated with 
EDTA, was washed twice 1/50 with HBSS at room temperature (r.t.), then 
incubated at 37°C 1/50 with FACSflow (Becton Dickinson) for 30 min, washed 
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once more with FACSflow at 37°C, and resuspended in the original volume. 100 
µl portions of the washed blood were then incubated for 30 min at r.t. with 1 µl 
FITC-labelled mouse monoclonal anti-human CD19 (Sigma) and 4 µl of PE-
labelled mouse monoclonal anti-human IgG (Pharmingen), or isotype control. The 
erythrocytes were then lysed by adding 2 ml of FACS Lysing Solution (Becton 
Dickinson) for 10 min, washed once with FACSflow at r.t. and analysed by flow-
cytometry (FACScan, Becton Dickinson). For expression of IgM+ the method was 
similar but the antibody was 5 µl PE-labelled polyclonal goat anti-human IgM 
(Sigma). 
    For CD40 ligand expression on T-cells, whole blood of the patient and a 
healthy control was diluted 1 in 10 with Iscove’s medium and incubated without 
stimulants or with 0·5 μM PMA and 1·25 μM ionomycin for 4 hr at 37°C, 5% 
CO2. Cells were then labelled with anti-human CD40L-PE and anti-human CD69-
FITC (Becton Dickinson) followed by lysis of red cells, washing, and analysis by 
flow-cytometry as above. CD40 expression on B-cells was checked with 1 µl 
FITC-labelled mouse monoclonal anti-human CD19 (Sigma) and 10 µl PE-
labelled mouse monoclonal anti-human-CD40 (Pharmingen) on 100 µl fresh 
blood. 
    For measurement of apoptosis, PBMC were prepared from ~12 ml of 
heparinised blood, washed 3 times with complete medium, and incubated in a 
culture flask in 10 ml of complete medium for 1-3 hr at 37°C in a 5% CO2 
atmosphere to enrich the suspension for lymphocytes by removing adherent cells 
(mainly monocytes). Non-adherent cells in the supernatant were adjusted to 1·25 × 
106 cells/ml and a sample (5 × 105 cells) removed (day 0). The remaining cells 
were cultured in 12-well flat-bottomed culture plates with 1 ml/well, 106 cells/ml, 
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in complete medium alone or with 1/250 pokeweed mitogen or dexamethasone 
100 µM, and sampled at days 5 and 8. Sampled cells were permeablised by 
adding an equal volume of ice-cold 70% ethanol and incubating on ice for 15 min, 
then washed once with FACSflow and stained overnight with propidium iodide 
(50 µg/ml) in the dark at 4°C. Next day, cells were washed with FACSflow and 
data acquired by cytometry (FACScalibur, Becton Dickinson). 
 
Immunoglobulin gene cloning and analysis 
RNA was prepared from PBMC with RNAzol B (obtained through Biogenesis 
Ltd, Poole, U.K.) according to the manufacturer’s instructions. cDNA was 
prepared by reverse-transcription with the SuperScript preamplification system 
(Life Technologies, Gibco BRL) according to the manufacturer’s instructions 
using the following gene-specific Ig-constant-region primers: for IgG heavy 
chain, the ‘CγA’ primer;25 for κ light chain, HuCKRT and for IgM heavy chain, 
HuCMRT (Table 1). 
    IgG and IgM heavy chain cDNA were amplified by PCR with the VH3-
30/3-33 leader primer HuVH3-30BACK2 (Table 1) and either the IgG heavy 
chain constant region primer ‘CγB’25 or the IgM constant region primer 
HuCMFOR (Table 1), and κ light chains with the Vκ family III leader primer 
HuVKIIIBACK and the kappa constant region primer HuCKFOR (both as in 
Table 1) with the Expand High Fidelity PCR System (Roche), 3·5 units/50 µl hot-
start reaction, using AmpliWax Gem 50 wax beads (Perkin Elmer) and 1·25 × the 
enzyme buffer as recommended in the wax beads instructions, with final 
concentrations of 2 mM MgCl2, 200 µM of each dNTP, 400 nM of each primer 
for heavy chains and 80 nM for light chains, and 1 - 3 µl of RT-reaction product 
Table 1 
about here 
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as cDNA template. Cycling conditions were 95°C, 2 min, followed by cycles of 
94°C for 1 min, annealing at 70°C for IgG and IgM heavy-chain genes and 67°C 
for κ-chain DNA, all 1 min, then 72°C 2 min, 45 cycles for the heavy chains, 40 
for κ chain, followed by 15 min at 72°C. 
    The products were separated by electrophoresis on agarose gels and stained 
with ethidium bromide. Appropriately sized bands were excised and the DNA 
extracted with a QIAquick gel extraction kit (QIAgen), ligated into the pCR2.1 
vector (‘Original TA cloning kit’, Invitrogen), and cloned in E. coli INVαF´. 
DNA was recovered from single white colonies using QIAgen or Macherey-Nagel 
plasmid miniprep kits, sequenced on an ABI sequencer with fluorescent dye-
terminators, and compared with the ‘V Base’ database of genomic human Ig DNA 
sequences (MRC Centre for Protein Engineering, Cambridge, U.K.) to identify the 
gene segments used and the mutations that have occurred. If any other 
sequence(s) had the same V, D and J the new sequence was then compared with 
them to (i) exclude contamination from PCR products of other subjects (ii) 
exclude any identical sequences from the same individual and (iii) identify related 
sequences with the same rearrangement but different mutations. All non-identical 
sequences with the same V segment from the same individual were aligned 
against the parent genomic sequence using BBEdit Lite and DNAPlot software for 
translation of all mutations and comparison of sequences. 
 
TNFSF5 (CD40-ligand gene) genomic and cDNA inspection 
Genomic DNA was prepared from blood using the QIAamp DNA Blood Minikit 
(QIAgen). Coding sequences of TNFSF5 exons with flanking intronic or 
untranslated sequence were amplified using the following primers: Exon 1, 40L1S 
 11
and 40L1A (Table 1); Exon 2, primers of Shimadzu et al.;27 Exon 3, 40L3S 
(Table 1) and the antisense primer of pair 4 of Lin et al.;28 Exon 4, 40L4S and 
40L4A (Table 1); Exon 5, 40L5S and 40L5A (Table 1). PCR was carried out as 
for Ig genes with 80 nM primer concentrations, 45°C annealing for Exons 1 – 4 
and 55°C for Exon 5, and 45 cycles for all. RNA was prepared as for Ig genes but 
from activated PBMC prepared as described29 and cDNA was prepared by reverse 
transcription as for Ig genes but with an oligo-dT primer. The complete coding 
sequence of TNFSF5 cDNA was then amplified with Primer P1 of Seyama et al.29 
and primer 40L5A (Table 1). All PCR products were gel-purified and sequenced 
as for Ig gene DNA and the results were compared with sequences in the NCBI 
database. 
 
RESULTS 
Immunoglobulin expression on B-cells 
Fluorescence cytometry showed that similar percentages of the patient’s and a 
healthy control’s PBL were B-cells, 9 - 12 % on separate occasions (normal range 
8 – 33 %30). 99·3 % of the patient’s B-cells registered as IgM+ compared with 
89·0 % of the control’s. In contrast, < 1% of the patient’s B-cells were IgG+ 
compared with about 5 % of the control’s (Fig. 1). Fig. 1 
about here 
 
Non-functionality in rearranged IgG genes 
We amplified rearranged genes with the commonly used VH segment, VH3-30. 
The leader sequences of VH3-30.3, VH3-30.5 and VH3-33 are the same as that of 
VH3-30, so rearranged genes using these segments were also amplified and 
examined. VH3-30 has 5 alleles and VH3-33 has 2, the others having only one 
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known allele. VH3-30.5 has a sequence identical to one of the alleles of VH3-30, 
reducing the total possible number of different sequences to 8. All these genomic 
alleles have the same length and only a few base-differences. 
    The characteristics of the rearranged IgG heavy-chain sequences cloned from 
the patient are summarised in Table 2, and the details of the sequences 
shown in Fig. 2. Of 40 sequences cloned, there were 22 different sequences, 
of which only three were functional, and these all had exactly the same VDJ 
junction (Rearrangement 1 in Fig. 2) and were therefore derived from clonally-
related B-cells. Among the non-functional sequences there were two pairs of 
clonally-related sequences and two groups of three clonally-related sequences, 
giving a total of 14 different rearrangements. Only Rearrangement 1 was both 
functional and completely normal. Rearrangement 2 was unusual in having no D 
segment but it was in frame and might have been functional. However, all three 
related sequences bearing this junction had a mutation producing a stop-codon in 
the VH segment. Non-functional immunoglobulin genes can be generated either 
during V(D)J rearrangement or by mutation. All the other 12 of the patient’s IgG 
rearrangements were non-functional due to the nature of the junction, either being 
out of frame, having D-segments in frames that generated stop-codons, having a 
stop-codon in the P/N bases, or a combination of these. 
Table 2 
and Fig. 2 
about here 
    In 7 healthy controls a total of 72 different rearranged IgG cDNA sequences 
were examined and all junctions were functionally rearranged. Two of these 
sequences were non-functional due to frame-shifts within the V segments. Both of 
these may have been PCR artefacts as, in each case, the frame-shift occurred at a 
run of like bases and one of the sequences was identical to a functional sequence 
except for the frame-shift. 
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 Functionality of other rearranged Ig genes 
To determine whether the patient might have a general defect of Ig gene 
rearrangement, his rearranged kappa-chain genes were cloned. All of the 10 
sequences examined were functional and none were related. Since class-switching 
to IgG changes the constant region expressed without changing the VHDJH 
rearrangement, we examined the patient’s IgM heavy-chain sequences. 18 were 
examined and again all were functional, and none related. The HCDR3 sequences 
of the μ-chain transcripts are shown in Fig. 3. Fig. 3 
about here 
 
Length of junctions and HCDR3s in the patient’s rearranged heavy-chain 
genes 
Table 3 shows the lengths of the HCDR3s and all their components. The mean 
HCDR3 length of the IgG rearrangements is greater than that of the IgM 
rearrangements, but not in all components. The VH and JH components of the IgG 
HCDR3s are slightly shorter than those of the IgM rearrangements and the D 
segments slightly longer, and these approximately cancel out. In those 
rearrangements in which the D segments could be identified, the difference in 
mean HCDR3 length is approximately equal to the number of extra N base-pairs. 
Table 3 
about here 
 
Somatic mutation rate 
Somatic mutations are detected by comparing rearranged gene sequences with 
unrearranged genomic sequences. Somatic hypermutation of rearranged Ig genes 
occurs throughout the length of the VH, D and JH segments. However, as sequence 
changes also occur at the VH-D and D-JH junctions as part of the rearrangement 
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process, later somatic mutation at these places cannot be detected easily in 
peripheral blood B-cells. Therefore base-changes were only counted within the 
VH segments of the rearranged genes for comparison within and between subjects. 
Further, they were only counted up to the end of ‘codon 92’ (Chothia 
nomenclature) because some bases may be deleted from the end of the VH 
segment during rearrangement. This region comprises 96 codons, i.e. 288 bp, the 
full length of the VH segments examined being 296 bp. 
    The average number of base changes per VH segment in γ-chain transcripts for 
each control subject ranged between 10·5 changes (3·65%) and 28 changes (9·7%) 
and the overall average was 7·12% for the 7 control subjects. 
    In the patient, as shown in Table 2, the number of mutations in non-functional 
γ-chain genes was generally low but the three clonally related functional genes 
had 20 base-changes in common with two having a further 2 common and one of 
those having one more. With so few functional sequences, it is not possible to 
determine the patient’s true average mutation rate in functionally rearranged 
genes, but these results – which give a figure of 7·5% - suggest that the mutation 
mechanism is not impaired. The two clonally related γ-chain sequences with 
additional base-changes were obtained from a blood sample taken 5 months after 
the first, showing long-term survival of cells with this functional rearrangement. 
    Of the 18 μ-chain transcripts, 16 had 0 – 2 mutations, one had 6, and one had 7. 
The overall mutation rate was 0·44%. Because cells expressing IgM were far 
more abundant than those expressing IgG, most if not all the κ transcripts are 
likely to have come from cells expressing IgM and hence would not be expected 
to be heavily mutated; they had 0 - 5 base-substitutions in the Vκ segment. 
    In view of the bias towards transitions at C·G base-pairs reported in patients 
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with mutations in UNG,17 the different types of base-substitution were also 
counted. In their work on UNG17 and HIGM4,22 Imai et al. found a mean of 4% of 
bases substituted in the IgM heavy-chain transcripts of CD19+CD27+ memory B-
cells. The rate of mutation in the IgM transcripts from our patient’s unsorted cells 
was lower, as would be expected, so we investigated the transitions and 
transversions in the V segments of all transcripts: IgM heavy chains, functional 
and non-functional IgG heavy chains, and κ chains (Fig. 4). There was no 
transition bias in mutations at C·G base-pairs, though it is possible that there was 
some mild disturbance of mutation balance. Imai et al. gave the percentage of 
mutations at C·G base-pairs as 63·6% with a range of 62 – 66 in 7 control subjects 
while in our patient it was only 55%. Also, in comparison with their figures, our 
patient appears to have fewer G → C and more C → G mutations than expected, 
and also fewer C → T mutations, but this may just be due to small numbers. 
 
Apoptosis of peripheral blood mononuclear cells 
The finding that such a high proportion of γ-chain sequences were non-functional 
suggested that there must be surviving B-cells with no functional Ab. These cells 
would normally be eliminated by apoptosis. To test the hypothesis that this 
process is defective in our patient, apoptosis of PBL before and after culture in the 
presence of apoptosis inducers was assessed. No deficit in the ability of the 
patient’s PBMC to enter apoptosis was demonstrated (Fig. 5). 
Fig. 5 
about here  
 
 
Genetic testing for hyper-IgM syndromes 
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CD154 (CD40 ligand) gene, TNFSF5: The patient’s activated T-cells showed 
normal CD154 expression by flow cytometry compared with healthy controls. In 
case the protein carried mutations affecting its function, the gene was also 
examined. Sequences of the five exons, amplified from genomic DNA, showed no 
mutations in coding sequences but two differences from the database sequence of 
intron 2 (accession no. D31795) were seen in four independent PCRs. There was 
replacement of C by A at the –57 position with respect to the beginning of Exon 
3, and insertion of an A residue between positions –53 and –52. These differences 
do not affect RNA splicing as the cDNA showed only a single product and the 
sequence was normal. 
CD40: Surface-expression of CD40 on the patient’s B-cells was normal. All four 
patients so far reported with mutations of the CD40 gene, TNFRSF5, have lacked 
surface expression of CD40,15,16 and since the patient’s cells also exhibited CSR 
and SHM, the gene itself was not sequenced. 
The AICDA (AID) and UNG genes were assessed for us by the laboratory of Anne 
Durandy (Hôpital Necker-Enfants Malades, Paris) and no abnormalities were 
found. 
The (NEMO) gene, IKBKG, was not studied as the patient did not have 
hypohydrotic ectodermal dysplasia. 
 
DISCUSSION 
We present a novel case of an immunodeficient patient, originally diagnosed  
with common variable immunodeficiency who subsequently demonstrated raised 
IgM, in whom nearly all IgG heavy-chain transcripts from unsorted peripheral 
blood lymphocytes are non-functional. Since V(D)J rearrangement has an 
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approximately 2/3 chance of producing a non-functional result, and cells making 
such rearrangements may survive if they make a functional rearrangement on the 
paired chromosome, non-functional rearrangements are commonly found amongst 
V(D)J clones from chromosomal B-cell DNA. Our finding of non-functional 
transcripts, however, is highly unusual. We found no non-functional 
rearrangements amongst γ-chain transcripts from 7 healthy controls and, in our 
patient, all the μ- and κ-chain transcripts were functional. Chromosomal VDJ 
amplifications are carried out with V and J primers, because the constant-region 
exons are far downstream, so it is usually not known whether switching has 
occurred in the non-functional rearrangements, but our finding that all non-
functional transcripts were γ-chains has not to our knowledge been reported 
previously. We conclude that either non-functional rearrangements were switched 
from Cμ to Cγ, or functional genes were switched and became non-functional 
afterwards.  
    Of the six hyper-IgM types described so far, this patient, with a history of 
recurrent bacterial but not opportunistic infections, lymphadenopathy without 
giant germinal centres, normal rate of hypermutation in his few functional IgG 
transcripts, and lack of transition bias, approximates best to the description of 
HIGM4.22 Furthermore, genetic testing has ruled out HIGM1, 2 and 3, and UNG 
deficiency, and he does not exhibit hypohydrotic ectodermal dysplasia seen in 
patients with NEMO gene mutations. His age at diagnosis (39 years) was rather 
older than that of any of the 15 HIGM4 patients described (range 0·3 – 23 years) 
but he has a history of recurrent infections since adolescence. Like the HIGM4 
patients described, he also had normal numbers of circulating lymphocytes, and 
normal percentages of T-cells and NK cells. His first B-cell percentage was below 
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the normal range but was normal on subsequent occasions. 
    In HIGM4, transcripts from excised circular DNA from Cμ to Iε were not 
detected, and ‘functional’ IgG and IgE transcripts (VH-C) were both either in 
reduced quantities or undetected in different patients.22 The method was RT-PCR. 
Sequencing was only performed on IgM transcripts from sorted IgM+CD27+ B-
cells, so it is not known whether the IgG and IgE transcripts were functional in 
terms of being in frame and without stop-codons. The transcripts in memory cells 
would be expected to be functional or differentiation to memory cells would 
surely not have occurred. Our observation of non-functional IgG transcripts in 
unsorted B-cells therefore does not rule out HIGM4 in our patient. 
    Four possible explanations might be considered for our finding that a high 
proportion of γ-chain transcripts were non-functional while all μ-chain transcripts 
were functional: 
 
1. There is no selection for B-cells with functional IgG, i.e. these cells are not 
given a survival signal. 
2. There is no selection against B-cells that do not express any functional Ig, i.e. 
these cells are not deleted by apoptosis. 
3. There is selection against cells bearing functional IgG. 
4. Secondary rearrangement of VHDJH segments (receptor revision31,32) is taking 
place soon after switching to IgG and much of this renders previously 
functional genes non-functional. 
 
    Most of our γ-chain transcripts were non-functional because of the nature of the 
rearrangements rather than mutation. This included the use of D-segments in 
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frames that read with stop codons, and J-segments out of frame with V segments. 
Therefore, the first three possibilities raise at least three problems: (a) they assume 
that non-functional VDJ rearrangements are class-switched from IgM to IgG, 
though we have been unable to find any evidence for this in the literature; (b) at 
least some cells with functional IgG are long-lived since the three functional IgG 
transcripts found were clonally related and two of them were derived from a blood 
sample taken five months after the one from which the first was amplified; (c) 
apoptosis of PBL is normal or even increased in the patient (Fig. 4). 
    On the other hand, evidence for secondary rearrangement after class-switching 
is also slim. To produce the observed non-functional rearrangements from 
previous functional ones would have required in some cases frame change at the 
VH-D junction (achievable by VH replacement or open-and-shut recombination), 
in other cases change at the D-JH junction (possibly achievable by JH replacement 
or open-and-shut recombination), and yet in other cases change at both junctions 
(to change the frame of the D segment whilst preserving the relationship of JH to 
VH). Hints that such processes could have occurred are restricted to: (i) the 
finding that the number of N base-pairs is greater at both VH-D and D-JH junctions 
in the IgG transcripts than in the IgM, significantly so in the former, while the 
lengths of other components of the HCDR3s are unchanged. Segment replacement 
tends to increase the number of N base-pairs33 while the alternative possibility - of 
selection reducing HCDR3 length in the functional IgM – tends to reduce all 
components, not just the Ns.34 (ii) the presence of bases in VH-D junctions that 
could have belonged to previous in-frame VH segments, although these are too 
short to provide strong evidence (data not shown) (iii) the observation of two 
possible cryptic RSS heptamers created by somatic hypermutation in the patient’s 
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μ sequences (underlined in Fig. 3) suggesting that JH replacement might be 
possible. 
    Imai et al.22 concluded that in their HIGM4 cases there was a selective CSR 
defect downstream of AICDA activity, but suggested as an alternative that there 
might be a deficiency of a factor required for the survival of switched B-cells. The 
latter could also apply in our case but it would require the deficiency to occur only 
in cells with functional Ig genes. It will be interesting to know whether the 
switched gene transcripts in their cases also have a high proportion of non-
functional ones. 
    In summary, we have found a case of hyper-IgM syndrome with no known 
genetic defect whose features correspond closely to the description of HIGM4. 
Rearranged IgM and κ transcripts are all functional but IgG transcripts are nearly 
all non-functional, suggesting that there is a cell-survival anomaly in switched B-
cells (and possibly receptor revision after class-switching). 
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